Governance

STEVEN FOSTER, MBA

CHAIR OF BOARD

Mr. Steven Foster is the Business Manager at Lawson Imaging, a branch of the Lawson Health Research Institute, which is a recognized leader in non-invasive biomedical imaging with new developments in hybrid imaging platforms such as PET/CT, SPECT/CT and MR/PET currently being applied to the areas of cardiology, neurology (including mental health), metabolic disease and cancer. Lawson Health Research Institute, located in London, Ontario, is one of Canada’s largest and most respected hospital-based research institutes and works in partnership with The University of Western Ontario.

 

 

 


KARIMAH ES SABAR

DIRECTOR

Karimah Es Sabar is CEO and Partner of Quark Venture Inc.

In her role as CEO & Partner at Quark Venture Ms. Es Sabar is also a Director of the Global Health Sciences Fund (GHS Fund), which was co-established with GF Securities, Hong Kong and which is one of the largest health sciences venture funds.

Prior to joining Quark Venture, Ms. Es Sabar led the Centre for Drug Research and Development (CDRD) as Canada’s national translation centre. She has an expansive global career spanning multi-national pharmaceutical/biotechnology companies (most notabl Sanofi Pasteur), start-ups, not-for-profit organizations and venture investment. Ms. Es Sabar has an extensive international experience and network, as well as leadership in marketing, business development, investment, strategic alliances, global collaborations and public private partnerships. She has raised enormous public and private sector funding, brought products to market, and has also developed and executed innovation and translation strategies in the life science sector and in biotech investment.

Ms. Es Sabar has received multiple awards and recognition for her pioneering work, including Canada’s Most Powerful Women: Top 100 Award. She holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management; an MSc degree in Neurochemistry from the Institute of Psychiatry University of London, England ‒ and a BSc Joint Honours degree in Biochemistry/Chemistry from the University of Salford in Manchester, England.

Ms. Es Sabar has served on numerous private and public boards including the National Research Council Canada, Providence Healthcare Research Institute and the Vancouver Prostate Centre, as well as several health technology companies. Currently, she is Board Chair for TRIUMF Innovations and Chair of the Health Biosciences Economic Strategy Table for Government of Canada. As a thought leader on innovation ecosystems and on public private partnerships, she is a frequent keynote speaker.


KATHRYN HAYASHI

DIRECTOR

Ms. Hayashi is the President and CEO of TRIUMF Innovations. Prior to TRIUMF Innovations, Ms. Hayashi was the Founding Chief Financial Officer of The Centre for Drug Research and Development (CDRD) and CDRD Ventures Inc, Canada’s national drug development and commercialization engine. As part of the founding team that started CDRD in 2007, she worked to develop a new partnership based model for translating and commercializing Canadian innovation and secure public and private sector funding totaling more than $230M. At CDRD she worked with a strong business-focused team to complete multiple transactions including the creation of 6 spin out companies (including a significant M&A exit) to establish CDRD as a leader in pre-clinical translational research and commercialization. Ms. Hayashi also presides as a Director and Audit Committee Chair of the Center for Commercialization and Cancer Immunotherapy at the Hôpital Maisonneuve-Rosemont and has served on the boards of several CDRD spinoff companies. Ms. Hayashi has over 25 years of industry experience in all areas of operational and strategic planning, finance, and governance, and is a member of the Institute of Chartered Accountants of British Columbia.


JAMES SCHLOSSER

DIRECTOR

Mr. James Schlosser is Senior Manager, Business Development & Contracts with the Provincial Health Authority’s Technology Development Office (TDO). In his role with the TDO, James is responsible for working closely with researchers from the BC Cancer Agency to take their promising inventions or discoveries to market. Prior to joining the TDO James was an investment analyst for Lions Capital, an investment banking and fund management firm which managed two venture capital funds, BC Advantage Funds (VCC) Ltd. and Lions Liquidity Investment Fund I LP, which invested in early stage life science and technology companies. James holds a BSc Biology from the University of Victoria and a BSc(Honours) in Oenology & Viticulture and an MSc Biology from Brock University.

 

 


LEN DUCKER

DIRECTOR

Mr. Len Ducker is President and General Manager of New Clear Horizons Consulting.  A career spanning more than 35 years in molecular imaging and radiopharmaceuticals, Mr. Ducker began his career at the McMaster Central Radiopharmacy In Hamilton ON followed by a Quality Management role with AECL’s  radiopharmaceutical division in Ottawa ON. 

He joined GE Healthcare Canada Inc (formerly Amersham Canada) and held various commercial roles throughout his thirty plus years. During this period, he was responsible for launching more than a dozen new products into the Canadian market, including the first cerebral perfusion agent for the assessment of stroke, epilepsy and dementia; the first WBC infection imaging technology for bone and inflammatory bowel disease and Canada’s first brachytherapy seed treatment for prostate cancer.  Co-founded the Nuclear Medicine Alliance of Canada, a strategic ensemble comprised of industry and professional members across Canada representing common interests to Health Canada’s BGTD.  Sat as Industry Co-Chair for the Federal Government’s Expert Working Group for Positron Emitting Radiopharmaceuticals, FDG.

For more than twelve years, serving as Vice President and General Manager of GE Healthcare Canada Inc, Mr. Ducker  established GE Healthcare’s Canadian footprint in central radiopharmacy operations and went on to pioneer the first successful private public partnership for radiopharmacies in Canada.  


CHARLES S. CONROY

CEO

Mr. Conroy is the Chief Executive Officer (CEO) of ARTMS Products. Mr. Conroy brings to ARTMS more than 25 years of experience in the life sciences industry, including several significant senior positions within the radiopharmaceutical industry. Most recently Mr. Conroy was the General Manager of Jubilant Pharma where he was responsible for North American sales and operations. Prior to joining Jubilant, he was the Chief Operating Officer of PharmBlue LLC, a nationwide specialty pharmacy business focusing on the federal 340B drug program, retroviruses, mental and behavioral health, custom compounding, and pain management.

Previously, he was the Senior Director of Pharmacy Operations managing Express Scripts’ flagship pharmacy at the Technology and Innovation Center in St. Louis, Missouri. In that capacity, Mr. Conroy was responsible for launching the latest technology and refining operational processes to ensure that over 40 million prescriptions were filled annually. For his efforts, he was given the Chairman’s Award, a distinction given to only a handful of top performers.  While at Express Scripts, Mr. Conroy also led UBC’s Patient Assistance Programs and Call Centers operations in St Louis, overseeing 1,200 clinical, clerical and administrative personnel who served over 50 different Pharma corporations.

Mr. Conroy has held a variety of roles with increasing responsibility at Amerinet (Intalere), Covidien, Eli Lilly and Nycomed Amersham (GE Healthcare).

Mr. Conroy earned a Bachelors in Science, Pharmacy from Purdue University and a Masters of Business Administration from the University of Michigan.  Mr. Conroy was among the first to earn his Board Certification in Nuclear Pharmacy (BCNP)  and is a registered pharmacist in 17 states.